Hot Info: Sma

Spinal Muscular Atrophy Types I, II, and III belong to a group of hereditary diseases that cause weakness and wasting of the voluntary muscles in the arms and legs of infants and children.

Spinal Muscular Atrophy is a term applied to a number of different disorders, all having in common a genetic cause and the manifestation of weakness due to loss of the motor neurons of the spinal cord and brainstem.

We are looking for patients of any age with SMA diagnosed before age 19 years.

FSMA is dedicated to promoting and supporting research, helping families cope through informational programs and support, and educating the public and the medical community about SMA.

A severe infantile form of the disease can also occur in boys because of missense and synonymous variants mutations in gene UBE1 on the X chromosome.

Spinal muscular atrophy is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.

In most cases a diagnosis can be made by the SMN gene test, which determines whether there is at least one copy of the SMN1 gene by looking for its unique sequences in exons 7 and 8.

The Pediatric Neuromuscular Clinical Research Network is conducting a “Clinical Study of Spinal Muscular Atrophy”.

The region of chromosome 5 that contains the SMN gene has a large duplication.

This booklet is intended to serve as a source of information and support for children and adults with Spinal Muscular Atrophy.

The muscles closer to the center of the body are usually more affected in spinal muscular atrophy than are the muscles farther from the center.

The disorders are caused by an abnormal or missing gene known as the survival motor neuron gene , which is responsible for the production of a protein essential to motor neurons.

He is shown in this news story in his swing and stroller, which were sent to him by Families of Spinal Muscular Atrophy.

If you or your child has been told the diagnosis is SMA but it’s not the SMN-related type, you’ll need to talk with your doctor and perhaps a genetic counselor to find out more about the genetics and prognosis for the particular SMA involved.

Also, the standard method of manual strength testing does not allow to grade small differences.

Spinal Muscular Atrophy is a genetic condition in which the muscles throughout the body are weakened because the cells in the spinal cord and motor nerves do not work properly.

Symptoms include floppy limbs and trunk, feeble movements of the arms and legs, swallowing difficulties, a weak sucking reflex, and impaired breathing.

The Spinal Muscular Atrophy Project is an NINDS funded collaborative program focused on the development of drug therapies for the treatment of SMA.

Your doctor can help you with details of maintaining respiratory health, including clearance of secretions and perhaps assisted ventilation.

Visit Our MDA News Section and Research News for Updates.

Researchers at the University of Milan published a paper in the “Journal of Clinical Investigation” showing transplant of spinal cord neural stem cells into mice with Spinal Muscular Atrophy improves survival and function.

Infants with Type 1 SMA have a life expectancy of less than two years, however, some grow to be adults.

Type II also known as juvenile SMA, intermediate SMA, or chronic SMA, has an onset between 6 and 18 months.

The onset is sudden and dramatic.

SMA is characterized by muscle weakness and decreased muscle tone.

The new treatment is given to patients under very controlled circumstances to make sure that participants are safe and so that any important changes noted among treated patients can be attributed to the treatment and not to external factors.

Many children with SMA start to show a scoliotic curve early in life, which is often treated with a brace until the right time for surgery is reached.

Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient’s medical history.

A great story about the strong bond between the two that has been beneficial to both patient and doctor.

Often there are additional copies of SMN2, and an increasing number of SMN2 copies causes less severe disease.